VAUDREUIL-DORION, QUEBEC–(Marketwired – April 27, 2017) – Immunotec Inc. (TSX VENTURE:IMM), a direct-to-consumer company and a leader in the nutritional industry (the “Company” or “Immunotec”), reports the results of its Annual General Meeting of Shareholders held today (“AGM”).
At the AGM, shareholders approved the appointment of all directors proposed for election, which comprised the existing slate of directors other than Dieter Beer, who chose not to stand for re-election for personal reasons and was replaced at the AGM by Lina Roti. Shareholders also approved the reappointment of Pricewaterhouse Coopers LLP as the Company’s auditor.
Lina Roti is a Chartered Professional Accountant (CPA) and also holds a Bachelor of Arts (Mathematics major) (1985) from Concordia University and a Graduate Diploma in Public Accountancy (1989) from McGill University. She currently acts as a controller and finance director to a number of companies, most of which operate in real estate investment and management.
In acknowledging Dieter Beer’s contribution to Immunotec, Rod Budd, Chairman of the Board of Directors, stated “We wish to thank Dieter Beer, co-founder of Immunotec, for his years of valuable services to the Board of Directors. He has been instrumental in implementing and sustaining Immunotec’s vision to position Immunocal® as a global nutritional choice, in order to improve many more lives with this incredible research-based product. We are confident that his legacy will carry on through Immuno Holding S.A. de C.V., and look forward to the successful conclusion of their proposed acquisition of Immunotec.”
The special meeting of shareholders of Immunotec in order to approve the transaction with Immuno Holding S.A. de C.V. is scheduled to be held on Thursday, May 11, 2017 at 10:00 a.m. (Montreal time) at the Company’s offices located at 300 Joseph-Carrier Street, Vaudreuil-Dorion, Québec. The Management Proxy Circular in connection with such meeting has been mailed to shareholders and is available under the profile of Immunotec at www.sedar.com.
About Immunotec Inc.
Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance. Please visit us at www.immunotec.com for additional information.
The Company files its continuous disclosure documents, on the SEDAR database at www.sedar.com and on the Company’s Website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This press release contains statements that constitute “forward-looking information” or “forward-looking statements” (collectively “forward-looking information”) within the meaning of applicable securities legislation. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “forecast”, “target”, “project”, “may”, “will”, “should”, “could” or similar words suggesting future outcomes or language suggesting an outlook.
Forward-looking information contained in this press release is based on the current beliefs of the Company as well as assumptions made by, and information currently available to, the Company. Although the Company considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect.
By its very nature, the forward-looking information included in this press release involves inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking information will not be achieved. Readers are cautioned not to place undue reliance on this forward-looking information as a number of important factors could cause the actual results to differ materially from those expressed in such forward-looking information. These factors include, but are not limited to, those risks associated with obtaining all of the judicial, regulatory and securityholder approvals necessary to allow for the completion of the transaction with Immuno Holding S.A. de C.V. in accordance with its terms. Readers are cautioned that the foregoing list of factors that may affect future results is not exhaustive. For information identifying further known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking information, please refer to the heading “Risks and Uncertainties” in Immunotec’s most recent Management’s Discussion and Analysis which can be found at www.sedar.com.
When relying on forward-looking information to make decisions with respect to Immunotec, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking information contained in this press release is made as of the date of this press release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.
CA, CF Vice-President and Chief Financial Officer
(450) 510-4527
